EP4055005A1 — Liquid melphalan composition
Assigned to Intas Pharmaceuticals Ltd · Expires 2022-09-14 · 4y expired
What this patent protects
The present invention related to a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with…
USPTO Abstract
The present invention related to a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salts thereof. The said stable ready to dilute pharmaceutical composition is further diluted to obtain a final diluted melphalan composition before administering to the patient in need thereof. Further, the present invention provides process for the preparation of the said composition and its use for the treatment of multiple myeloma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.